Xenon Pharmaceuticals (Canada)

Recent papers from Xenon Pharmaceuticals (Canada)

1. Discovery of Novel Bicyclic Pyrazole Amides as Potent Neuronal KV7 Potassium Channel Openers with Strong Preclinical Antiseizure ActivityACS Medicinal Chemistry Letters · 2026
2. Selective Potentiation of NaV1.1 Channels by Small Molecule XPC-837 in Dravet Mice Suppresses Spontaneous Seizures, Prevents SUDEP, and Increases Long Term Potentiation (S19.004)Neurology · 2026
3. Examining the Impact of Comorbid Depression on Healthcare Utilization, Cost, and Outcomes in Patients with Newly Diagnosed Epilepsy in the US (S41.002)Neurology · 2026
4. Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults with Focal Epilepsy: ≥42-Month Interim Analysis of the Ongoing 7-year X-TOLE Open-label Extension (P11-10.001)Neurology · 2026
5. Results From the Phase 3 X-TOLE2 Study Evaluating Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults With Focal Onset Seizures (FOS) (LS1.007)Neurology · 2026
6. What does it mean to live with epilepsy? Burden of illness from the patient perspective.2026
7. Expanded genetic alphabet increases structural and chemical diversity of six-letter DNA for high-affinity protein-targeting aptamersNature Communications · 2025
8. Development of a Continuous Flow Synthesis of Ezogabine: Process Optimization and Scale-UpOrganic Process Research & Development · 2025
9. Half-life prediction of central nervous system (CNS) small molecules in humans using gradient tree boostingFuture Medicinal Chemistry · 2025
10. The Pharmacokinetic and Pharmacodynamic Relationship of Clinically Used Antiseizure Medications in the Maximal Electroshock Seizure Model in RodentsInternational Journal of Molecular Sciences · 2025
11. Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive DisorderJAMA Network Open · 2025
12. Clinicopathologic Features and the Spectrum of Myelokathexis in Warts, Hypogammaglobulinemia, Infections, Myelokathexis SyndromeLaboratory Investigation · 2025
13. The venom of Cyriopagopus schmidti spider contains a natural huwentoxin-IV analogue with unexpected improved analgesic potentialFrontiers in Pharmacology · 2025
14. Interim analysis of the long‐term efficacy and safety of azetukalner in an ongoing open‐label extension study following a phase 2b clinical trial (X‐ TOLE ) in adults with focal epilepsyEpilepsia Open · 2025
15. Genetic Variants in the SCN9A Gene are Detected in a Minority of Erythromelalgia PatientsActa Dermato Venereologica · 2025
16. Opportunistic Scheduling With Beam Focusing in Distributed RIS-Aided MU-MIMO SystemsIEEE Open Journal of the Communications Society · 2025
17. Accuracy of a Rapid-Response EEG's Automated Seizure-Burden EstimatorNeurology · 2024
18. Rational Design of Macrocyclic Noncovalent Inhibitors of SARS-CoV-2 M pro from a DNA-Encoded Chemical Library Screening Hit That Demonstrate Potent Inhibition against Pan-Coronavirus Homologues and Nirmatrelvir-Resistant VariantsJournal of Medicinal Chemistry · 2024
19. Diastereoselective Hydrodifluoromethylation of Alkenyl N-Heterocycles via Photocatalytic Radical-Polar CrossoverThe Journal of Organic Chemistry · 2024
20. Antiseizure Medication Use and Outcomes After Suspected or Confirmed Acute Symptomatic SeizuresJAMA Neurology · 2024